Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

34.93USD
22 Mar 2017
Change (% chg)

-- (--)
Prev Close
$34.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
630,249
52-wk High
$42.48
52-wk Low
$19.32

ACAD.OQ

Chart for ACAD.OQ

About

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease... (more)

Overall

Beta: 3.91
Market Cap(Mil.): $4,240.77
Shares Outstanding(Mil.): 121.41
Dividend: --
Yield (%): --

Financials

  ACAD.OQ Industry Sector
P/E (TTM): -- 48.48 30.07
EPS (TTM): -2.33 -- --
ROI: -75.54 -2.48 13.05
ROE: -75.58 5.24 14.20

BRIEF-Acadia Pharmaceuticals Q4 loss per share $0.65

* Acadia Pharmaceuticals reports financial results for the fourth quarter and year ended december 31, 2016

Feb 28 2017

Bets on financials, pharma power U.S. hedge funds' strong start to year

NEW YORK Several big-name U.S. hedge fund investors in the fourth quarter moved significant parts of their portfolios into financial and pharmaceutical stocks that are expected to benefit under the Trump administration, helping to power the sector to its best January performance in four years.

Feb 14 2017

Bets on financials, pharma power U.S. hedge funds' strong start to year

NEW YORK, Feb 14 Several big-name U.S. hedge fund investors in the fourth quarter moved significant parts of their portfolios into financial and pharmaceutical stocks that are expected to benefit under the Trump administration, helping to power the sector to its best January performance in four years.

Feb 14 2017

Acadia says Alzheimer's psychosis drug clears mid-stage study

Acadia Pharmaceuticals Inc said on Tuesday its drug to treat psychosis in patients suffering from Alzheimer's disease met its main goal in a mid-stage study, sending its shares up as much as 18.5 percent.

Dec 20 2016

BRIEF-Acadia Pharmaceuticals initiates phase II trial of Pimavanserin

* Acadia Pharmaceuticals initiates phase II trial of Pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia Source text for Eikon: Further company coverage:

Nov 15 2016

BRIEF-UK's CMA says accepted proposals in Acadia's Priory Group deal

Nov 10 UK's Competition and Markets Authority (CMA):

Nov 10 2016

BRIEF-Acadia Pharmaceuticals initiates phase III trial of pimavanserin for adjunctive treatment in patients with Schizophrenia

* Acadia Pharmaceuticals initiates phase iii trial of pimavanserin for adjunctive treatment in patients with Schizophrenia Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-Acadia Pharmaceuticals initiates phase II study of pimavanserin in Alzheimer's disease agitation

* Acadia Pharmaceuticals initiates phase II study of pimavanserin in Alzheimer's disease agitation Source text for Eikon: Further company coverage:

Oct 31 2016

GM to add 650 jobs at Spring Hill factory to meet SUV demand

General Motors said it would add a third shift and 650 jobs at its factory in Spring Hill, Tennessee to meet higher demand for its recently launched Cadillac XT5 and GMC Acadia crossover SUVs.

Oct 11 2016

More From Around the Web

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $34.47 +0.22
Eli Lilly and Co (LLY.N) $84.36 +0.63
Eisai Co., Ltd (4523.T) ¥5,983 +33.00

Earnings vs. Estimates